Literature DB >> 28711533

Cerebral Vasospasm-Dependent and Cerebral Vasospasm-Independent Cerebral Infarctions Predict Outcome After Nonaneurysmal Subarachnoid Hemorrhage: A Single-Center Series with 250 Patients.

Juergen Konczalla1, Sepide Kashefiolasl2, Nina Brawanski2, Markus Bruder2, Florian Gessler2, Christian Senft2, Joachim Berkefeld3, Volker Seifert2, Stephanie Tritt3.   

Abstract

OBJECTIVE: The number of patients with nonaneurysmal subarachnoid hemorrhage (naSAH) has increased during the last decade. Data regarding infarctions in naSAH are still limited. The aim of this study was to identify the rate of cerebral vasospasm (CVS)-dependent and CVS-independent infarctions and their influence on clinical outcomes.
METHODS: Between 1999 and 2015, 250 patients suffering from naSAH were analyzed retrospectively. A delayed infarction was analyzed whether it was associated with CVS (CVS-dependent infarction) or not (CVS-independent).
RESULTS: A total of 36 patients (14%) had cerebral infarctions. CVS was detected in 54 patients (22%), and 15 (6%) of them developed infarctions (CVS-dependent). Infarctions without signs of CVS (CVS-independent) occurred in 21 patients (8%). Overall, 86% of the patients had favorable outcome. Patients without cerebral infarctions had the best outcome (91% favorable outcome, 5% mortality rate). Patients with CVS-independent infarctions (57%) as well as patients with CVS-dependent infarctions (53%) had a favorable outcome less often. The mortality rate was also significantly greater in patients with CVS-independent (19%) and CVS-dependent infarctions (33%). A further independent predictor was anticoagulative therapy, which increased during study period and was associated with nonperimesencephalic blood distribution.
CONCLUSIONS: CVS-dependent and independent infarctions occur in naSAH and contribute to unfavorable outcomes. Whereas CVS-independent infarctions occur in any subgroup, CVS-dependent infarctions seem to be associated with blood pattern (Fisher 3). Anticoagulative therapy seems to be not only a predictor for worse outcome but also for nonperimesencephalic SAH. Accordingly, the proportion of perimesencephalic and nonperimesencephalic SAH changed during the study period (from 2.2:1 to 1:1.7).
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Cerebral vasospasm; Delayed cerebral infarctions; Fisher 3; Nonperimesencephalic; Perimesencephalic; Subarachnoid hemorrhage

Mesh:

Year:  2017        PMID: 28711533     DOI: 10.1016/j.wneu.2017.07.017

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?

Authors:  Chen-Yu Ding; Fang-Yu Wang; Han-Pei Cai; Xiao-Yong Chen; Shu-Fa Zheng; Liang-Hong Yu; Yuan-Xiang Lin; Zhang-Ya Lin; De-Zhi Kang
Journal:  Chin Neurosurg J       Date:  2020-04-04

Review 2.  Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: towards a potential target therapy?

Authors:  Davide Marco Croci; Sivani Sivanrupan; Stefan Wanderer; Guilherme J Agnoletto; Alessio Chiappini; Basil E Grüter; Lukas Andereggen; Luigi Mariani; Philipp Taussky; Serge Marbacher
Journal:  Neurosurg Rev       Date:  2021-08-27       Impact factor: 2.800

3.  Tocilizumab Reduces Vasospasms, Neuronal Cell Death, and Microclot Formation in a Rabbit Model of Subarachnoid Hemorrhage.

Authors:  Davide M Croci; Stefan Wanderer; Fabio Strange; Basil E Grüter; Sivani Sivanrupan; Lukas Andereggen; Daniela Casoni; Michael von Gunten; Hans Rudolf Widmer; Stefano Di Santo; Javier Fandino; Luigi Mariani; Serge Marbacher
Journal:  Transl Stroke Res       Date:  2021-01-06       Impact factor: 6.829

Review 4.  Current status of perimesencephalic non-aneurysmal subarachnoid hemorrhage.

Authors:  Kun Hou; Jinlu Yu
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.